Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States
ConclusionThese results suggest that canagliflozin 300 mg is likely to provide better health outcomes at a lower overall cost than dapagliflozin 10 mg in patients with T2DM inadequately controlled with metformin from the perspective of the United States health care system.FundingJanssen Scientific Affairs, LLC and Janssen Global Services, LLC.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
More News: Canagliflozin | Dapagliflozin | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Fortamet | Forxiga | Health Management | Insulin | Invokana | Metformin | SGLT2 Inhibitors | Sodium | Study | USA Health